Stress & Adrenal
Cortisol Replacement Therapy: Dosage, Mechanism, and Outcomes
Cortisol replacement therapy is a life-sustaining treatment for people with adrenal insufficiency — but dosing it correctly is surprisingly complex. Many patients remain under- or over-replaced for years, with significant consequences for energy, immune function, and metabolic health.
Cortisol Replacement Therapy: Dosage, Mechanism, and Outcomes
Cortisol replacement therapy is medically necessary for people with primary adrenal insufficiency (Addison's disease), secondary adrenal insufficiency, or congenital adrenal hyperplasia (CAH) — not an optional wellness upgrade. If your adrenal glands cannot produce cortisol, replacement is non-negotiable. The main caveat: dosing is highly individual, and most people on replacement are either slightly over- or under-dosed at any given time. The exception is adrenal fatigue — a subclinical, unverified diagnosis that does not warrant pharmaceutical cortisol replacement.
---
What Is Cortisol Replacement Therapy?
Cortisol is a glucocorticoid produced by the adrenal cortex in response to ACTH signaling from the pituitary. In healthy adults, cortisol secretion follows a diurnal rhythm: levels peak within 30–45 minutes of waking (the cortisol awakening response), then decline through the day. Total daily secretion is approximately 5–10 mg of cortisol, though older estimates placed it as high as 20–30 mg — numbers now considered inflated by early radioisotope methodology (Esteban et al., Journal of Clinical Endocrinology & Metabolism 1991; PMID: 1956525).
When this secretion fails — due to autoimmune destruction of the adrenal glands, pituitary damage, or long-term glucocorticoid therapy causing HPA axis suppression — exogenous cortisol must replace it. The pharmaceutical forms used are:
| Drug | Equivalent Dose | Duration of Action | Notes |
|---|---|---|---|
| Hydrocortisone | Reference (20 mg = ~10 mg cortisol) | 4–6 hours | Preferred for its physiologic profile |
| Cortisone acetate | 25 mg ≈ 20 mg hydrocortisone | 6–8 hours | Requires hepatic conversion to cortisol |
| Prednisolone | 5 mg ≈ 20 mg hydrocortisone | 12–36 hours | Used when compliance with multiple doses is difficult |
| Dexamethasone | 0.5 mg ≈ 20 mg hydrocortisone | 36–54 hours | Longest-acting; risk of over-replacement |
Hydrocortisone is the current clinical standard for adrenal insufficiency because its half-life most closely mirrors endogenous cortisol (Bornstein et al., European Journal of Endocrinology 2016; PMID: 27272198).
---
Clinical Dosing Protocol for Hydrocortisone
Modern dosing guidelines recommend lower doses than were used historically. The target is to mimic the physiologic rhythm rather than simply replace a fixed daily total.
Standard maintenance dosing:
- Total daily dose: 15–25 mg hydrocortisone, divided across 2–3 doses
- Morning dose: 10–15 mg, taken immediately upon waking (to replicate the cortisol awakening response)
- Midday dose: 5 mg, taken 4–6 hours after the morning dose
- Late afternoon dose (if needed): 2.5–5 mg, no later than 4 PM to avoid disrupting sleep
A landmark study by Debono et al. (Journal of Clinical Endocrinology & Metabolism 2009; PMID: 19190110) using continuous subcutaneous hydrocortisone infusion demonstrated that replicating the natural cortisol rhythm improved well-being, fatigue, and quality-of-life scores compared to conventional twice-daily oral dosing in patients with adrenal insufficiency.
Sick-day rules (stress dosing):
Patients must double or triple their dose during febrile illness, surgery, or significant physical trauma. Failure to do so risks an adrenal crisis — a medical emergency with mortality rates of 6–10% per crisis event (Hahner et al., Journal of Clinical Endocrinology & Metabolism 2015; PMID: 25419883).
Monitoring:
There is no reliable blood test to confirm optimal cortisol replacement. Serum cortisol levels reflect exogenous drug levels, not physiologic adequacy. Clinicians assess by:
- Symptom review (fatigue, salt craving, weight, mood)
- Blood pressure and electrolytes
- Body weight trends (over-replacement causes cushingoid features)
- Bone density monitoring (over-replacement accelerates bone loss)
---
DHEA Replacement Therapy in Adrenal Insufficiency
Cortisol is not the only adrenal hormone lost in primary adrenal insufficiency. The adrenal cortex also produces dehydroepiandrosterone (DHEA) and its sulfate ester DHEA-S — androgens that serve as precursors for sex hormone synthesis and have independent effects on mood, immune function, and lean mass.
Serum DHEA-S is typically undetectable in patients with Addison's disease. Several randomized controlled trials have evaluated add-on DHEA replacement at doses of 25–50 mg/day in women with adrenal insufficiency, with the most consistent findings in improved mood, sexual function, and general well-being (Arlt et al., New England Journal of Medicine 1999; PMID: 10580070). The effect in men is less pronounced because testicular androgen production partially compensates.
For readers interested in how DHEA acts across a broader hormonal context, the article on how long DHEA takes to work and clinical dosage considerations covers its pharmacokinetics in more detail.
DHEA replacement in adrenal insufficiency is endorsed by the Endocrine Society as a reasonable adjunct — particularly for women with persistent fatigue, low libido, or mood issues despite adequate glucocorticoid and mineralocorticoid replacement. The usual protocol is 25–50 mg taken in the morning to align with the natural DHEA diurnal pattern.
---
Pregnenolone Replacement Therapy: The Upstream Precursor
Pregnenolone sits at the top of the adrenal steroid synthesis pathway — it is the direct precursor to DHEA, progesterone, and ultimately cortisol. In states of adrenal insufficiency or HPA axis dysfunction, pregnenolone synthesis is also impaired, though this receives far less clinical attention than cortisol replacement.
Pregnenolone itself has not been approved as a pharmaceutical replacement therapy in the same way hydrocortisone has, but it is an area of growing clinical interest. Small studies suggest that pregnenolone supplementation (50–500 mg/day in research settings) may improve neurological symptoms, fatigue, and cognitive function in populations with low adrenal output, although large-scale RCT evidence remains limited.
For a detailed breakdown of how pregnenolone interacts with the testosterone and hormonal axis, the clinical guide to pregnenolone dosage and mechanism provides additional context on its downstream effects.
It is important not to conflate pregnenolone supplementation with pharmaceutical cortisol replacement — they act at very different points in the pathway and are used for different clinical indications. Someone with confirmed adrenal insufficiency requires medically supervised hydrocortisone; pregnenolone is not a substitute.
---
Growth Hormone Replacement Therapy and the Adrenal Connection
Growth hormone (GH) deficiency frequently co-occurs with adrenal insufficiency, particularly in hypopituitarism — where pituitary damage disrupts both ACTH (needed to stimulate cortisol) and GH secretion simultaneously. This connection matters for cortisol replacement because GH influences cortisol metabolism: growth hormone accelerates the conversion of cortisone to active cortisol by upregulating 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in peripheral tissues.
When GH replacement is initiated in a patient already on hydrocortisone for hypopituitarism, their cortisol exposure effectively increases — because more cortisone is being converted to active cortisol. This can unmask previously subclinical adrenal insufficiency in patients with partial ACTH deficiency, or cause relative over-replacement in those already on full doses (Giavoli et al., Clinical Endocrinology 2004; PMID: 15239740). The practical implication: when GH replacement therapy is started or adjusted, hydrocortisone doses often need to be reviewed and potentially lowered.
Growth hormone replacement itself (recombinant human GH, e.g., somatropin) is dosed by weight or lean body mass, typically 0.2–0.4 mg/day subcutaneously in adults, titrated by IGF-1 levels. It is a prescription-only treatment managed by endocrinologists and is outside the scope of over-the-counter supplementation.
---
Oxytocin Replacement Therapy and Adrenal Stress Physiology
Oxytocin is sometimes discussed alongside adrenal hormones because of its opposing relationship with the cortisol stress response. Oxytocin attenuates HPA axis activation — it reduces ACTH secretion and cortisol output in response to psychosocial stress, acting as a biological buffer against chronic stress-driven adrenal overactivation (Neumann & Landgraf, Progress in Brain Research 2012; PMID: 22305783).
Intranasal oxytocin has been studied in the context of social anxiety, post-traumatic stress disorder, and stress reactivity — not as a replacement for cortisol in adrenal insufficiency, but as a modulator of an overactive HPA axis. Doses used in trials range from 16–40 IU intranasally. However, oxytocin replacement therapy is not a standard clinical treatment for adrenal conditions, and intranasal formulations have inconsistent CNS delivery.
The relevance to cortisol physiology is mechanistic: people with chronically elevated cortisol (from stress, not adrenal insufficiency) may benefit from strategies that down-regulate HPA axis reactivity. Oxytocin is one pathway; adaptogenic herbs like ashwagandha (KSM-66) operate through a different mechanism — reducing cortisol by modulating the HPA axis response to perceived stress rather than replacing the hormone directly.
---
Risks of Over- and Under-Replacement
Getting the dose wrong in either direction carries real clinical consequences:
Under-replacement:
- Persistent fatigue and post-exertional malaise
- Salt craving, hypotension, hyponatremia
- Risk of adrenal crisis during illness or surgery
- Impaired immune response
- Reduced quality of life (documented in multiple patient-reported outcome studies)
Over-replacement:
- Cushingoid features (central weight gain, facial fullness, striae)
- Insulin resistance and increased type 2 diabetes risk
- Osteoporosis (glucocorticoids suppress osteoblasts and increase osteoclast activity)
- Hypertension
- HPA axis further suppression
- Cardiovascular risk elevation
A 2018 analysis by Quinkler et al. found that the average hydrocortisone dose prescribed in Germany was approximately 30 mg/day — substantially higher than the 15–20 mg now recommended — suggesting that a significant proportion of patients on replacement therapy have historically been chronically over-replaced (Quinkler et al., European Journal of Endocrinology 2018).
---
What This Means for Your Formula
Cortisol replacement therapy in the pharmaceutical sense requires a physician's prescription and careful monitoring — it is not something a supplement platform manages. However, for individuals with subclinical HPA axis dysregulation (elevated morning cortisol, blunted cortisol awakening response, high perceived stress without adrenal insufficiency), targeted supplementation can meaningfully support adrenal function.
When Ones analyzes your blood work and health data, the AI looks at markers including cortisol patterns (if wearable or lab data includes them), DHEA-S levels, and stress burden indicators to identify whether adrenal support is warranted. Relevant ingredients from the Ones catalog include:
- KSM-66 Ashwagandha (600 mg): The most clinically studied adaptogen for HPA axis regulation. An 8-week double-blind RCT by Chandrasekhar et al. (Indian Journal of Psychological Medicine 2012; PMID: 23439798) in 64 adults found KSM-66 reduced serum cortisol by 27.9% versus placebo, with significant reductions in perceived stress scores. Ones includes this at the full 600 mg clinical dose.
- Adrenal Support System Blend: Ones' proprietary Adrenal Support blend is formulated for individuals showing markers of adrenal stress. It combines adaptogenic and nutritive compounds targeting HPA axis regulation — useful as a complement to lifestyle interventions for those without confirmed adrenal insufficiency.
- Rhodiola Rosea: At doses of 200–400 mg of standardized extract, rhodiola has demonstrated cortisol-modulating effects in high-stress populations and supports the adrenal response to physical and cognitive stressors.
For individuals managing confirmed adrenal insufficiency on pharmaceutical hydrocortisone, any supplement additions should be discussed with their endocrinologist — adrenal support herbs are not a replacement for prescribed cortisol, and some adaptogens may theoretically interact with HPA axis feedback.
If you're also looking at how lipid markers and metabolic health intersect with adrenal hormone patterns, the guide to managing triglycerides through diet and supplementation provides useful context on the metabolic downstream effects of chronic cortisol elevation.
---
Key Takeaways
- Cortisol replacement therapy is medically necessary for confirmed adrenal insufficiency; it is not a treatment for vague fatigue or subclinical stress.
- The modern standard is hydrocortisone 15–25 mg/day divided across 2–3 doses, timed to mimic the physiologic cortisol rhythm.
- DHEA replacement (25–50 mg/day) is a reasonable adjunct for women with adrenal insufficiency who have persistent fatigue or mood issues despite adequate glucocorticoid replacement.
- Pregnenolone sits upstream of cortisol in the steroid synthesis pathway and is an area of clinical interest, but is not a pharmaceutical substitute for hydrocortisone.
- Growth hormone replacement can alter cortisol metabolism via 11β-HSD1, requiring hydrocortisone dose review when GH therapy is initiated.
- For individuals without adrenal insufficiency who show signs of HPA axis dysregulation, evidence-based adaptogens like KSM-66 ashwagandha at 600 mg can reduce cortisol by roughly 28% — but always consult a healthcare provider before modifying any prescribed hormonal therapy.